Pharma
-
Avadel’s $2.1 Billion Deal With Alkermes Could Shake Up Sleep Medicine—Here’s How!
Avadel Pharmaceuticals’ $2.1B acquisition by Alkermes underscores Lumryz’s strong growth and profitability, with added upside tied to FDA approval for…
Read More » -
The Novavax Crisis Deepens: Why Shah Capital Wants Out Now!
Novavax faces pressure from a major shareholder Shah Capital to explore a sale as it struggles with weak revenue, poor…
Read More » -
Harrow’s MELT Acquisition Could Disrupt IV Sedation—But Is It The Hottest Pharma Small-Cap Buy?
Harrow Inc. targets Melt Pharma buyout to expand sedation portfolio with MELT-300, a sublingual non-IV sedative, aiming for U.S. launch…
Read More » -
Y-mAbs’ $412 Million Take-Private Offer From SERB Poised To Upset The Oncology Landscape
Y-mAbs Therapeutics stunned investors when SERB Pharmaceuticals announced an all-cash bid to take the company private at $8.60 per share,…
Read More » -
Abbvie’s $1 Billion Gilgamesh Gambit: The Deal That Could Rewrite Its Future!
AbbVie’s recent confirmation that it’s in talks to acquire Gilgamesh Pharmaceuticals for roughly $1 billion underscores its unrelenting push to…
Read More » -
Merck’s $10 Billion Bet On Verona: Smart Strategic Pivot Or Costly Diversion From The Keytruda Cliff?
Merck has made headlines yet again with its $10 billion acquisition of Verona Pharma, a bold move aimed at cushioning…
Read More » -
Eli Lilly’s Obesity Pill Could Be a Game-Changer — But Here’s Why Zepbound Already Has a Giant Lead
Eli Lilly has taken a commanding position in the obesity drug market with its GLP-1 agonist Zepbound, and now the…
Read More » -
Hims & Hers Stock Plunges After Novo Nordisk Breakup: What Really Happened?
Hims & Hers Health saw its stock crash by over 35% in a matter of days after Novo Nordisk announced…
Read More » -
Eli Lilly’s $1.3 Billion Gene Editing Bet: What the Verve Deal Signals for the Future of Heart Disease!
Eli Lilly has expanded into cardiovascular treatment with its $1.3 billion acquisition of Verve Therapeutics, a clinical-stage gene-editing company focused…
Read More » -
ASBP: Unlocking Multi-Billion Dollar Markets with Enhanced Drug Delivery
Enter Aspire Biopharma, Inc. (NASDAQ: ASBP), a pioneering company enhancing existing drugs with their patent-pending, soluble sublingual technology. By delivering…
Read More »
